LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Puma Biotechnology Inc

Затворен

СекторЗдравеопазване

3.7 1.93

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.69

Максимум

3.73

Ключови измерители

By Trading Economics

Приходи

-16M

3M

Продажби

-13M

46M

P/E

Средно за сектора

4.212

51.198

EPS

0.1

Марж на печалбата

6.464

Служители

172

EBITDA

-14M

4M

Препоръки

By TipRanks

Препоръки

Продай

12-месечна прогноза

-17.81% downside

Дивиденти

By Dow Jones

Следващи печалби

31.07.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

3.8M

163M

Предишно отваряне

1.77

Предишно затваряне

3.7

Настроения в новините

By Acuity

50%

50%

166 / 380 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

Puma Biotechnology Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.06.2025 г., 14:31 ч. UTC

Печалби

New York State Retirement Fund Posts 5.84% Annual Investment Return

6.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

6.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

6.06.2025 г., 20:33 ч. UTC

Печалби

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6.06.2025 г., 19:36 ч. UTC

Пазарно говорене

Oil Futures Post Solid Weekly Gains -- Market Talk

6.06.2025 г., 19:28 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

6.06.2025 г., 18:46 ч. UTC

Пазарно говорене

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

6.06.2025 г., 18:02 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Continues to Decline -- Market Talk

6.06.2025 г., 16:35 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6.06.2025 г., 16:34 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6.06.2025 г., 16:21 ч. UTC

Пазарно говорене

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

6.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

6.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

6.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

6.06.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

6.06.2025 г., 16:07 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

6.06.2025 г., 16:07 ч. UTC

Пазарно говорене

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

6.06.2025 г., 15:53 ч. UTC

Пазарно говорене

Mexican Inflation Seen Rising in May -- Market Talk

6.06.2025 г., 15:36 ч. UTC

Пазарно говорене

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

6.06.2025 г., 15:36 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

6.06.2025 г., 15:33 ч. UTC

Пазарно говорене

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

6.06.2025 г., 15:16 ч. UTC

Пазарно говорене

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

6.06.2025 г., 15:05 ч. UTC

Пазарно говорене

Silver at its Highest In Nearly 15 Years -- Market Talk

6.06.2025 г., 14:35 ч. UTC

Пазарно говорене

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

6.06.2025 г., 14:28 ч. UTC

Пазарно говорене

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

6.06.2025 г., 14:28 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

6.06.2025 г., 14:28 ч. UTC

Пазарно говорене

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

6.06.2025 г., 14:15 ч. UTC

Пазарно говорене

Oil Rises on U.S.-China Talks Optimism -- Market Talk

6.06.2025 г., 14:12 ч. UTC

Печалби

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

6.06.2025 г., 14:09 ч. UTC

Печалби

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Puma Biotechnology Inc Прогноза

Ценова цел

By TipRanks

-17.81% надолу

12-месечна прогноза

Среден 3 USD  -17.81%

Висок 4 USD

Нисък 2 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Puma Biotechnology Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Продай

2 ratings

0

Купи

1

Задържане

1

Продай

Техническа оценка

By Trading Central

3.07 / 3.075Подкрепа & съпротива

Краткосрочен план

Weak Bullish Evidence

Средносрочен план

Weak Bullish Evidence

Дългосрочен план

Bullish Evidence

Настроение

By Acuity

166 / 380 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.